VacV Biotherapeutics is a cancer immunotherapy company developing innovative viral-based therapies for cancers. Launched in 2022 by cancer immunotherapy pioneers Professor Yaohe Wang, Professor Nicholas Lemoine, Dr. Louisa Chard Dunmall and Dr. Peng Liu, VacV employs a unique approach to immunotherapy based on the Vaccinia virus to stimulate a patient’s immune system to fight cancer while simultaneously destroying cancer cells. This approach offers many advantages over existing immunotherapies, including minimized toxicity, higher specificity and efficacy, allowing for efficient systemic delivery of an immunotherapy for the first time.
Company Details
- Employees
- 7
- Address
- London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://vacvbtx.com/
- HQ
- London
Vacv Biotherapeutics Questions
Vacv Biotherapeutics's website is http://vacvbtx.com/
Vacv Biotherapeutics's LinkedIn profile is https://uk.linkedin.com/company/vacv-biotherapeutics
Vacv Biotherapeutics has
7 employees.
View email and phone details for 7
employees at Vacv Biotherapeutics.
Vacv Biotherapeutics's industry is
Biotechnology Research
Vacv Biotherapeutics's top competitors are
Engitix Therapeutics,
Candel Therapeutics,
Nouscom,
Scancell,
Immunomic Therapeutics, Inc.,
Infinitopes,
Evaxion A/s,
Elicio Therapeutics,
Ose Immunotherapeutics,
Imugene Limited.
Vacv Biotherapeutics's categories are Biotechnology Research
